experienced in the management of these patients should also be considered. Additionally, patients with postorchiectomy beta-hCG levels >5,000 IU/L should undergo brain MRI because they are at an increased risk of having brain metastases. Further workup should
Search Results
Timothy Gilligan, Daniel W. Lin, Rahul Aggarwal, David Chism, Nicholas Cost, Ithaar H. Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L. Hancock, Chad LaGrange, Ellis G. Levine, Thomas Longo, Will Lowrance, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Philip Saylor, Kanishka Sircar, David C. Smith, Katherine Tzou, Daniel Vaena, David Vaughn, Kosj Yamoah, Jonathan Yamzon, Alyse Johnson-Chilla, Jennifer Keller, and Lenora A. Pluchino
Charles P. Borden, Charles L. Shapiro, Maria Teresa Ramirez, Linda Kotur, and William Farrar
the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer recommendation that all patients diagnosed with skeletal metastases receive bisphosphonates. The cancer program at OSUCCC uses a variety of tools for process
Robert J. Besaw, Adrienne R. Terra, Grace L. Malvar, Tobias R. Chapman, Lauren M. Hertan, and Benjamin L. Schlechter
UCOGC of the pancreas with a high tumor mutation burden (TMB) identified during next-generation sequencing (NGS). Third-line pembrolizumab monotherapy markedly reduced the primary pancreatic tumor and metastases in the lung and brain. Despite recent
Michael Karass, Rohan Bareja, Ethan Shelkey, Panagiotis J. Vlachostergios, Brian D. Robinson, Francesca Khani, Juan Miguel Mosquera, Douglas S. Scherr, Andrea Sboner, Scott T. Tagawa, Ana M. Molina, Olivier Elemento, David M. Nanus, and Bishoy M. Faltas
metastases were prospectively collected. Somatic DNA from tumor samples and germline DNA from peripheral blood mononuclear cells were submitted for WES as previously described. 3 RNA was extracted from tumor samples and submitted for RNA-seq. Whole
R. Michael Tuttle, Douglas W. Ball, David Byrd, Gilbert H. Daniels, Raza A. Dilawari, Gerard M. Doherty, Quan-Yang Duh, Hormoz Ehya, William B. Farrar, Robert I. Haddad, Fouad Kandeel, Richard T. Kloos, Peter Kopp, Dominick M. Lamonica, Thom R. Loree, William M. Lydiatt, Judith McCaffrey, John A. Olson Jr., Lee Parks, John A. Ridge, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, and Lori J. Wirth
aerodigestive tract compression or invasion are reported by up to 15% of patients with sporadic disease. 7 Symptoms from distant metastases in the lungs or bones occur in 5% to 10% of patients. The ability of the tumor to secrete measurable quantities of
Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold, and May T. Cho
treated initially with FOLFOX (5-FU/leucovorin/oxaliplatin). However, response imaging after 7 cycles showed progressive disease with new liver and lung metastases. He subsequently received 5 cycles of irinotecan and cetuximab but developed a small bowel
Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani
, including brain metastases, hemoptysis, or anticoagulation use. Survival Outcomes The primary outcome was OS, defined as the number of months from administration of first chemotherapy agent for metastatic disease until the date of death or end of the
Julie Hallet, Calvin Law, Simron Singh, Alyson Mahar, Sten Myrehaug, Victoria Zuk, Haoyu Zhao, Wing Chan, Angela Assal, and Natalie Coburn
gastric, small intestinal, colonic, and rectal. Metastatic disease was defined using ICD-9 and ICD-10 codes and divided into synchronous metastases (metastasis code ≤6 months from the date of NET diagnosis) and metachronous metastases (metastasis code >6
Puneeth Iyengar and Robert D. Timmerman
II NSCLC and isolated tumor metastases to the lungs, the standard approach to treatment has historically been surgical resection. For surgically resected stage I lesions, the 5-year overall survival (OS) rate is 60% to 70% in several series. 14 , 15
Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh
secondary local therapy may interrupt the natural history of disease and prevent progression to systemic disease. A basic question in this context is the extent to which this sequence of events—versus the presence of occult metastases at surgery
